Anthem Biosciences Limited (BOM:544449)
India
· Delayed Price · Currency is INR 661.50
-1.25 (-0.19%)
At close: Dec 4, 2025
Anthem Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Operating Revenue | 20,712 | 18,446 | 14,194 | 10,569 | 12,313 | 11,032 |
| Other Revenue | 58.37 | 58.37 | 8 | 9.82 | 95.09 | 21.77 |
| Revenue | 20,771 | 18,504 | 14,202 | 10,579 | 12,408 | 11,054 |
| Revenue Growth (YoY) | 22.34% | 30.29% | 34.24% | -14.74% | 12.24% | - |
| Cost of Revenue | 9,013 | 7,815 | 6,254 | 3,574 | 4,270 | 4,637 |
| Gross Profit | 11,757 | 10,689 | 7,948 | 7,005 | 8,137 | 6,417 |
| Selling, General & Admin | 2,582 | 2,623 | 1,844 | 1,540 | 1,379 | 1,426 |
| Other Operating Expenses | 1,469 | 1,292 | 1,039 | 1,103 | 982.96 | 843.76 |
| Operating Expenses | 5,157 | 4,809 | 3,702 | 3,280 | 2,940 | 2,893 |
| Operating Income | 6,600 | 5,880 | 4,246 | 3,725 | 5,197 | 3,524 |
| Interest Expense | -74.02 | -100.17 | -92.76 | -82.01 | -115.6 | -159.99 |
| Interest & Investment Income | 647 | 647 | 408.62 | 290.99 | 95.76 | 8.45 |
| Currency Exchange Gain (Loss) | 73.42 | 73.42 | 146.18 | 128.89 | 133.26 | 159.71 |
| Other Non Operating Income (Expenses) | 234.62 | -2.78 | -1.86 | 223.59 | 16.62 | 56.24 |
| EBT Excluding Unusual Items | 7,481 | 6,498 | 4,706 | 4,286 | 5,327 | 3,588 |
| Gain (Loss) on Sale of Investments | 75.78 | 75.78 | 71.8 | 68.97 | 135.99 | 69.47 |
| Gain (Loss) on Sale of Assets | -4.64 | -4.64 | -4.35 | -0.03 | -1.84 | -1.87 |
| Other Unusual Items | - | - | - | 618.02 | - | - |
| Pretax Income | 7,552 | 6,569 | 4,773 | 4,973 | 5,461 | 3,656 |
| Income Tax Expense | 2,390 | 2,056 | 1,100 | 1,121 | 1,406 | 942.72 |
| Net Income | 5,162 | 4,513 | 3,673 | 3,852 | 4,055 | 2,713 |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.01 |
| Net Income to Common | 5,162 | 4,513 | 3,673 | 3,852 | 4,055 | 2,713 |
| Net Income Growth | 13.57% | 22.86% | -4.64% | -5.02% | 49.48% | - |
| Shares Outstanding (Basic) | 560 | 559 | 567 | 570 | 570 | 547 |
| Shares Outstanding (Diluted) | 561 | 562 | 567 | 570 | 570 | 547 |
| Shares Change (YoY) | -1.04% | -0.96% | -0.61% | - | 4.33% | - |
| EPS (Basic) | 9.22 | 8.07 | 6.48 | 6.75 | 7.11 | 4.96 |
| EPS (Diluted) | 9.21 | 8.04 | 6.48 | 6.75 | 7.11 | 4.96 |
| EPS Growth | 14.75% | 24.11% | -4.03% | -5.04% | 43.27% | - |
| Free Cash Flow | 3,087 | 1,038 | -1,499 | 1,171 | 1,771 | 1,618 |
| Free Cash Flow Per Share | 5.51 | 1.85 | -2.64 | 2.05 | 3.10 | 2.96 |
| Gross Margin | 56.61% | 57.77% | 55.96% | 66.21% | 65.58% | 58.05% |
| Operating Margin | 31.77% | 31.78% | 29.89% | 35.21% | 41.89% | 31.88% |
| Profit Margin | 24.85% | 24.39% | 25.86% | 36.41% | 32.68% | 24.54% |
| Free Cash Flow Margin | 14.86% | 5.61% | -10.55% | 11.06% | 14.27% | 14.64% |
| EBITDA | 7,699 | 6,759 | 5,050 | 4,358 | 5,763 | 4,134 |
| EBITDA Margin | 37.07% | 36.53% | 35.56% | 41.19% | 46.45% | 37.40% |
| D&A For EBITDA | 1,099 | 878.75 | 804.85 | 633.27 | 566.06 | 610.8 |
| EBIT | 6,600 | 5,880 | 4,246 | 3,725 | 5,197 | 3,524 |
| EBIT Margin | 31.77% | 31.78% | 29.89% | 35.21% | 41.89% | 31.88% |
| Effective Tax Rate | 31.65% | 31.30% | 23.05% | 22.54% | 25.74% | 25.79% |
| Revenue as Reported | 21,807 | 19,303 | 14,831 | 11,340 | 12,802 | 11,404 |
| Advertising Expenses | - | 15.62 | 10.62 | 5.35 | 1.17 | 1.18 |
Source: S&P Capital IQ. Standard template. Financial Sources.